XML 58 R45.htm IDEA: XBRL DOCUMENT
v3.22.2.2

Investment in Cornerstone Pharmaceuticals (Details) - USD ($) shares in Millions, $ in Millions |  |  | 1 Months Ended | 12 Months Ended
--- | --- | --- | --- | ---
Oct. 01, 2021 | Jan. 31, 2019 | Oct. 28, 2022 | Sep. 24, 2021 | Jan. 28, 2021 | Jul. 31, 2022
Investment in Cornerstone Pharmaceuticals (Details) [Line Items] |  |  |  |  |  |
Ownership percentage in non-operating subsidiary |  |  |  |  |  | 50.00%
Principal amount |  | $ 10.0 |  |  |  |
Total impairment loss |  |  |  |  |  | $ 17.3
Noncontrolling interests |  |  |  |  |  | 79.1
Interest amount |  |  |  |  |  | $ 10.4
Rafael Pharmaceuticals [Member] |  |  |  |  |  |
Investment in Cornerstone Pharmaceuticals (Details) [Line Items] |  |  |  |  |  |
Ownership percentage in non-operating subsidiary |  |  |  |  |  | 90.00%
Fully diluted |  |  |  |  |  | 10.00%
Percentage of outstanding capital stock |  |  |  |  |  | 51.00%
Percentage of outstanding capital stock on fully diluted basis |  |  |  |  |  | 41.00%
Impairment charge |  |  | $ 79.1 |  |  |
CS Pharma Holdings, LLC [Member] |  |  |  |  |  |
Investment in Cornerstone Pharmaceuticals (Details) [Line Items] |  |  |  |  |  |
Ownership percentage in subsidiary and holds percentage of interest |  |  |  |  |  | 50.00%
Indirect interest in assets held, percentage |  |  |  |  |  | 45.00%
Fully diluted |  |  |  |  |  | 10.00%
Convertible promissory note, rate of interest |  | 3.50% |  |  |  |
Pharma Holdings [Member] |  |  |  |  |  |
Investment in Cornerstone Pharmaceuticals (Details) [Line Items] |  |  |  |  |  |
Ownership percentage in non-operating subsidiary |  |  |  |  |  | 90.00%
Exercise price of warrants or rights, description |  |  |  |  |  | The Company currently owns 51% of the issued and outstanding equity in Cornerstone Pharmaceuticals. Approximately 8% of the issued and outstanding equity is owned by the Company’s subsidiary CS Pharma and 43% is held by the Company’s subsidiary Pharma Holdings. The Company’s subsidiary Pharma Holdings holds the Warrant, which is non-dilutable and provides for the Company to increase its (via Pharma Holdings and CS Pharma and inclusive of the interests held by the other owners of those entities) total ownership to 56%. Based on the current shares issued and outstanding of Cornerstone Pharmaceuticals as of July 31, 2022, the Company, and the Company’s affiliates, would need to pay approximately $13.5 million to exercise the Warrant in full to 56%. On an as-converted fully diluted basis (for all convertible securities of Cornerstone Pharmaceuticals outstanding), the Company and the Company’s affiliates would need to pay approximately $118 million to exercise the Warrant in full (including to offset the impact of additional issuances of Cornerstone Pharmaceuticals equity under the Line of Credit, as defined below). The Instrument holds 10% of the interest in Pharma Holdings and would need to contribute 10% of any cash necessary to exercise any portion of the Warrant.
Exercise of warrants purchases, description |  |  |  |  | On January 28, 2021, Pharma Holdings partially exercised the Warrant to maintain the 51% ownership percentage and purchased 7.3 million shares of Cornerstone Pharmaceuticals’ Series D Preferred Stock for $9.1 million, of which $0.9 million was contributed by the holder of a minority interest in Pharma Holdings. |
Aggregate amount |  |  |  | $ 25.0 |  |
Agreement accrues interest per annum |  |  |  |  |  | 9.00%
Reserve amount |  |  |  |  |  | $ 25.0
Other amounts |  |  |  |  |  | 2.6
Interest income |  |  |  |  |  | 1.9
CS Pharma and Pharma Holdings [Member] |  |  |  |  |  |
Investment in Cornerstone Pharmaceuticals (Details) [Line Items] |  |  |  |  |  |
Interest amount |  |  |  |  |  | $ 6.9
Series D Convertible Preferred Stock [Member] |  |  |  |  |  |
Investment in Cornerstone Pharmaceuticals (Details) [Line Items] |  |  |  |  |  |
Exercise of warrants purchases, description |  |  |  |  |  | The Series D Convertible Preferred Stock has a stated value of $1.25 per share (subject to appropriate adjustment to reflect any stock split, combination, reclassification or reorganization of the Series D Preferred Stock or any dilutive issuances, as described below). Holders of Series D Stock are entitled to receive non-cumulative dividends when, as and if declared by the Board of Cornerstone Pharmaceuticals, prior to any dividends to any other class of capital stock of Cornerstone Pharmaceuticals. In the event of any liquidation, dissolution or winding up Cornerstone Pharmaceuticals, or in the event of any deemed liquidation, proceeds from such liquidation, dissolution or winding up shall be distributed first to the holders of Series D Stock. Except with respect to certain major decisions, or as required by law, holders of Series D Stock vote together with the holders of the other preferred stock and common stock and not as a separate class.
Series D Convertible Preferred Stock [Member] | CS Pharma Holdings, LLC [Member] |  |  |  |  |  |
Investment in Cornerstone Pharmaceuticals (Details) [Line Items] |  |  |  |  |  |
Exercise price of warrants or rights, description |  |  |  |  |  | Pharma Holdings holds 44.0 million shares of Cornerstone Pharmaceutical’s Series D Convertible Preferred Stock and a warrant to increase the combined ownership of Pharma Holdings and CS Pharma to up to 56% of the fully diluted equity interests in Cornerstone Pharmaceuticals (the “Warrant”). The exercise price of the Warrant is the lower of 70% of the price sold in an equity financing, or $1.25 per share, subject to certain adjustments.
Purchase of exercise the warrant, shares |  |  |  |  |  | 16.7
Howard Jonas [Member] | Rafael Pharmaceuticals [Member] |  |  |  |  |  |
Investment in Cornerstone Pharmaceuticals (Details) [Line Items] |  |  |  |  |  |
Fully diluted |  |  |  |  |  | 10.00%
First Advance [Member] | Pharma Holdings [Member] |  |  |  |  |  |
Investment in Cornerstone Pharmaceuticals (Details) [Line Items] |  |  |  |  |  |
Advance amount of debtor |  |  |  | $ 1.9 |  |
Second Advance [Member] | Pharma Holdings [Member] |  |  |  |  |  |
Investment in Cornerstone Pharmaceuticals (Details) [Line Items] |  |  |  |  |  |
Advance amount of debtor | $ 23.1 |  |  |  |  |

X
- Definition Description of exercise of warrants purchases. + References No definition available. + Details
Name: | rfl_ExerciseOfWarrantsPurchasesDescription
Namespace Prefix: | rfl_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Exercise Price Of Warrants Or Rights Description. + References No definition available. + Details
Name: | rfl_ExercisePriceOfWarrantsOrRightsDescription
Namespace Prefix: | rfl_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Fully diluted. + References No definition available. + Details
Name: | rfl_FullyDiluted
Namespace Prefix: | rfl_
Data Type: | dtr:percentItemType
Balance Type: | na
Period Type: | instant

X
- References No definition available. + Details
Name: | rfl_IndirectInterestAssetsPercentage
Namespace Prefix: | rfl_
Data Type: | dtr:percentItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | rfl_InvestmentinCornerstonePharmaceuticalsDetailsLineItems
Namespace Prefix: | rfl_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the purchase by the parent of an additional equity interest in a subsidiary during the period, thereby effecting a change in total (consolidated) equity attributable to the parent. The purchase of the additional equity interest represented by this element increases the parent's controlling interest in the subsidiary. + References No definition available. + Details
Name: | rfl_PercentageOfConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangesPurchaseOfInterestByParent
Namespace Prefix: | rfl_
Data Type: | dtr:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Percentage of outstanding capital stock. + References No definition available. + Details
Name: | rfl_PercentageOfOutstandingCapitalStock
Namespace Prefix: | rfl_
Data Type: | dtr:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Percentage of outstanding capital stock on fully diluted basis. + References No definition available. + Details
Name: | rfl_PercentageOfOutstandingCapitalStockOnFullyDilutedBasis
Namespace Prefix: | rfl_
Data Type: | dtr:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Potential ownership purchase. + References No definition available. + Details
Name: | rfl_PotentialOwnershipPurchase
Namespace Prefix: | rfl_
Data Type: | dtr:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number of shares purchase of exercise the warrant. + References No definition available. + Details
Name: | rfl_PurchaseOfExerciseWarrantShares
Namespace Prefix: | rfl_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Interest amount. + References No definition available. + Details
Name: | rfl_interestAmount
Namespace Prefix: | rfl_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of significant additions in the period in other assets (current, noncurrent, or unclassified). + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(17)) -URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 + Details
Name: | us-gaap_AdditionsToOtherAssetsAmount
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The average effective interest rate during the reporting period. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 835 -SubTopic 30 -Section 45 -Paragraph 2 -URI https://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 20 -Section 50 -Paragraph 1F -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.22(a)(1)) -URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 + Details
Name: | us-gaap_DebtInstrumentInterestRateDuringPeriod
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 20 -Section 50 -Paragraph 6 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 835 -SubTopic 30 -Section 45 -Paragraph 2 -URI https://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 835 -SubTopic 30 -Section 50 -Paragraph 1 -URI https://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.22(a)(1)) -URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 + Details
Name: | us-gaap_DebtInstrumentInterestRateEffectivePercentage
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Amount of expense (income) related to reorganization items classified as other. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 852 -SubTopic 10 -Section 45 -Paragraph 9 -URI https://asc.fasb.org/extlink&oid=124437977&loc=d3e55730-112764 + Details
Name: | us-gaap_DebtorReorganizationItemsOtherExpenseIncome
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of impairment loss from right-of-use asset from finance lease. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 842 -SubTopic 20 -Section 25 -Paragraph 5 -Subparagraph (c) -URI https://asc.fasb.org/extlink&oid=123399704&loc=SL77918425-209957 + Details
Name: | us-gaap_FinanceLeaseImpairmentLoss
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The amount of income taxes from which a reporting entity is exempt or for which it will receive a reduction in income taxes as a result of the income tax holiday granted by the taxing jurisdiction. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 11.C) -URI https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817 + Details
Name: | us-gaap_IncomeTaxHolidayAggregateDollarAmount
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Interest income generated from amounts on deposit with foreign entities located outside the United States of America. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 942 -SubTopic 220 -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04.4) -URI https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260 + Details
Name: | us-gaap_InterestIncomeForeignDeposits
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Carrying amount of equity interests owned by noncontrolling shareholders, partners, or other equity holders in one or more of the entities consolidated into the reporting entity's financial statements other than joint ventures, limited partnerships, operating partnerships or interests held by preferred unit holders. + References No definition available. + Details
Name: | us-gaap_OtherMinorityInterests
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition The cash inflow associated with the sale of equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 12 -Subparagraph (b) -URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585 + Details
Name: | us-gaap_ProceedsFromSaleOfEquityMethodInvestments
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Nonrecurring impairment charges related to the write-off of production-related equipment and inventory. This tag is used when an Entity charges this cost to cost of goods sold. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.2(a)) -URI https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227 + Details
Name: | us-gaap_ProductionRelatedImpairmentsOrCharges
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of increase in allowance for credit loss on security purchased under agreement to resell, from recovery. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 326 -SubTopic 20 -Section 50 -Paragraph 13 -Subparagraph (e) -URI https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447 + Details
Name: | us-gaap_SecuritiesPurchasedUnderAgreementsToResellAllowanceForCreditLossRecovery
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | srt_OwnershipAxis=rfl_RafaelPharmaceuticalsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_OwnershipAxis=rfl_CSPharmaHoldingsLLCMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_OwnershipAxis=rfl_PharmaHoldingsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_OwnershipAxis=rfl_CSPharmaAndPharmaHoldingsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementClassOfStockAxis=rfl_SeriesDConvertiblePreferredStockMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_TitleOfIndividualAxis=rfl_HowardJonasMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ShortTermDebtTypeAxis=rfl_FirstAdvanceMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ShortTermDebtTypeAxis=rfl_SecondAdvanceMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |